title: Animal models suggest the TRIP8b-HCN interaction is a therapeutic target for major depressive disorder.
authors.affiliation: a Davee Department of Neurology and Clinical Neurosciences , Northwestern University , Chicago , IL , USA.
authors.forename: Kyle A
authors.initials: KA
authors.lastname: Lyman
authors.affiliation: a Davee Department of Neurology and Clinical Neurosciences , Northwestern University , Chicago , IL , USA.
authors.forename: Ye
authors.initials: Y
authors.lastname: Han
authors.affiliation: a Davee Department of Neurology and Clinical Neurosciences , Northwestern University , Chicago , IL , USA.
authors.forename: Dane M
authors.initials: DM
authors.lastname: Chetkovich
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D064428:Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*
chemical_list: D000928:Antidepressive Agents; D064428:Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; C529762:PEX5L protein, human; D018160:Receptors, Cytoplasmic and Nuclear
keywords: HCN; Pex5; TRIP8b; depression; ion channel